<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839449</url>
  </required_header>
  <id_info>
    <org_study_id>Y-2004</org_study_id>
    <nct_id>NCT00839449</nct_id>
  </id_info>
  <brief_title>Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study</brief_title>
  <acronym>EVAS</acronym>
  <official_title>Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS): Effect of Eicosapentaenoic Acid on Cerebral Vasospasm Following Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yamaguchi University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nakamura Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Iwate Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tohoku University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ootemachi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yamaguchi University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of
      morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in
      the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits
      sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study
      examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral vasospasm occasionally seen after subarachnoid hemorrhage (SAH) due to a ruptured
      intracranial aneurysm is the most common cause of morbidity and mortality in these cases.
      Recent studies indicate that Rho-kinase plays an important role in such cerebral vasospasm
      and that numerous agents, such as thromboxane A2 (TXA2), sphingosylphosphorylcholine (SPC)
      and arachidonic acid (AA), can activate Rho-kinase directly or through receptors in the cell
      membrane; among these agents, SPC has been described as a novel messenger for
      Rho-kinase-mediated Ca2+ sensitization of vascular smooth muscle contraction.
      Eicosapentaenoic acid (EPA) has recently been reported to inhibit SPC-induced Rho-kinase
      activation in vitro, and thereby vascular smooth muscle contraction, through the inhibition
      of Src family protein tyrosine kinases translocation. Moreover, the concentration of AA
      increases in the cerebrospinal fluid of patients with SAH, suggesting that this substance has
      a potential role in the occurrence of cerebral vasospasm following SAH, while EPA is known to
      change the constitution ratios of AA and EPA in cell membrane phospholipid, resulting in the
      inhibition of TXA2 synthesis. These observations lead us to hypothesize that EPA may inhibit
      cerebral vasospasm following SAH through the inhibition of Rho-kinase activation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral vasospasms: Symptomatic vasospasm defined as documented arterial vasospasm consistent with new neurological deterioration. New low-density areas on CT scans associated with vasospasm.</measure>
    <time_frame>Between 4 and 30 days after the onset of SAH</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's Glasgow Outcome Scale (GOS).</measure>
    <time_frame>At 1 month after onset of SAH.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the group A are orally administered eicosapentaenoic acid ethyl ester.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the group B (control) are not administered eicosapentaenoic acid ethyl ester.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eicosapentaenoic acid ethyl ester</intervention_name>
    <description>Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ‚ÅÑ day) from the surgery next day to 30 days after the onset of SAH.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>EPADEL S900 TM (EPA ethyl ester, purity &gt;98%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subarachnoid hemorrhage (SAH)

          -  The ruptured cerebral aneurysms conformed by cerebral angiography

          -  The patients with treated by craniotomy and clip application within 72h after the
             onset of SAH

        Exclusion Criteria:

          -  Traumatic or mycotic aneurysms

          -  A history or complication of serious stroke

          -  Moya Moya disease

          -  A history of SAH

          -  Complication of serious heart or hepatic disease or infection or renal failure

          -  Malignant tumor

          -  Patients judged to be inappropriate by physician in charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiyasu Suzuki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yamaguchi University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ootemachi Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>803-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakamura Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Eicosapentaenoic acid Cerebral Vasospasm Therapy Study (EVAS) Group</name_title>
    <organization>Yamaguchi University Hospital</organization>
  </responsible_party>
  <keyword>subarachnoid hemorrhage</keyword>
  <keyword>cerebral vasospasm</keyword>
  <keyword>eicosapentaenoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

